While immune checkpoint blockade, particularly targeting Programmed Cell Death Protein 1 (PD-1), has emerged as a promising avenue, its efficacy in adjuvant settings is limited, with notable exceptions in cases of mismatch repair deficiency [2,4,5,6,7,8,9,10]. The gene discussed is PDCD1; the disease is mismatch repair cancer syndrome 1.